Company intelligence / Profile preview

AdjuTec Pharma AS

Ownership: Private
Development stage: Other

Overview

AdjuTec Pharma has completed a Phase I single-ascending dose (SAD) study for its lead product APC148, showing no serious side effects, with all reported events being mild and transient. The drug demonstrated linear concentration increase through all dose levels and was reduced in the body by 50% every 2.6 hours on average, mainly excreted through kidneys. The study involved 46 healthy adults split into six groups, with promising results supporting continued clinical development.[9]

Therapeutic areas: Infectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

5 assets

APC148

4 more assets in the full pipeline.

Partnerships

Clinical Trial Consultants (CTC)

Beyond the preview

Go deeper on AdjuTec Pharma AS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AdjuTec Pharma AS.